Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice
- 116 Downloads
The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.
KeywordsLung cancer Treatment Re-biopsy
KH has received honoraria outside the current work from AstraZeneca, Ono Pharmaceutical, Astellas, Novartis, BMS, MSD, Eli Lilly Japan, Daiichi-Sankyo Pharmaceutical, Boehringer-Ingelheim, Nihon Kayaku, Taiho Pharmaceutical, and Chugai Pharmaceutical. KH has also received research funding outside the current work from AstraZeneca, Boehringer-Ingelheim, Ono Pharmaceutical, Astellas, Novartis, BMS, Eli Lilly Japan, MSD, and Chugai Pharmaceutical. KK has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Sanofi-Aventis.
KH and others: collection, assembly, analysis, and interpretation of data. Drafting of the manuscript and critically reviewing or revising the manuscript for important intellectual content. All authors have approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
No other authors declare any conflicts of interest regarding this study.
- 7.Hotta K, Ninomiya K, Takigawa N et al (2015) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Jpn J Clin Oncol 45:603–604Google Scholar
- 17.National Comprehensive Cancer Network homepage. https://www.nccn.org/. Accessed 5 May 2018
- 29.Gadgeel S, Kowanetz F, Zou W et al Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L + NSCLC: Results from the randomized OAK study. ESMO 2017 (Abs 1296O)Google Scholar
- 32.Kato Y, Hotta K, Takigawa N et al (2014) Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 73:943–950CrossRefGoogle Scholar
- 34.Hotta K, Tabata M, Kiura K et al (2007) Gefitinib induces premature senescence in non-small-cell lung cancer cells with or without EGFR gene mutation. Oncol Rep 17:313–317Google Scholar
- 36.Kim TJ, Hong SA, Kim O et al (2017) Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Oncotarget 8:107630–107639Google Scholar
- 37.Kowanetz M, Socinski MA, Zou W et al (2018) IMpower150: Efficacy of atezolizumab plus bevacizumab and chemotherapy in 1L metastatic nonsquamous NSCLC across key subgroups. Presented at: 2018 AACR Annual Meeting, 2018; Chicago, Illinois. Abstract CT076Google Scholar